Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Swart

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Arthritis Research & Therapy|April 9, 2020
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication CommitteeGabriella Giancane, Joost F Swart, Elio Castagnola, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Rheumatology (Oxford, England)|September 11, 2021
Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate useJoeri W van Straalen, Roline M Krol, Gabriella Giancane, et al.
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 20, 2023
Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN VariantsRemco G A Erkens, Jorg J A Calis, Anouk Verwoerd, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Rheumatology (Oxford, England)|July 26, 2024
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR projectFrancesco Baldo, Remco G A Erkens, Mao Mizuta, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
Vaccine|May 17, 2023
Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort studyMilou Ohm, Joeri W van Straalen, Marieke Zijlstra, et al.
Pediatric Rheumatology Online Journal|September 17, 2018
Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocolCasper G Schoemaker, Wineke Armbrust, Joost F Swart, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Arthritis Research & Therapy|April 9, 2020
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication CommitteeGabriella Giancane, Joost F Swart, Elio Castagnola, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Rheumatology (Oxford, England)|September 11, 2021
Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate useJoeri W van Straalen, Roline M Krol, Gabriella Giancane, et al.
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 20, 2023
Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN VariantsRemco G A Erkens, Jorg J A Calis, Anouk Verwoerd, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Rheumatology (Oxford, England)|July 26, 2024
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR projectFrancesco Baldo, Remco G A Erkens, Mao Mizuta, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
Vaccine|May 17, 2023
Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort studyMilou Ohm, Joeri W van Straalen, Marieke Zijlstra, et al.
Pediatric Rheumatology Online Journal|September 17, 2018
Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocolCasper G Schoemaker, Wineke Armbrust, Joost F Swart, et al.
Pageof 12